Twenty-Five Year Political Veteran Sam Myers, Jr. Named President of Direct Impact
24.9.2019 19:52:00 EEST | Business Wire | Press release
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Sam Myers, Jr., has been named President of Direct Impact (DI), the nation's leading grassroots campaign firm and member of BCW Group. Myers is based in Washington, D.C., and is charged with building DI’s industry-leading work in developing local market campaigns that drive communities to take action around various public affairs, public education and corporate reputation issues.
“I am thrilled that Sam will be leading DI,” said Chris Foster, President of BCW North America. “His more than two decades of political campaign experience and having served at the highest levels of government will be invaluable to clients that are navigating increasingly complex communications and legislative environments.”
Myers has served in two presidential administrations and worked on six presidential campaigns. From 2009 to 2017 he served in the Obama administration, in multiple leadership roles. For the U.S. Department of Education, his efforts in the Office of the Secretary and as head of Office of the White House Liaison helped put in place policies that supported narrowing the skills gap, job creation, healthy eating in schools and America’s College Promise.
Myers also spearheaded change management and communication for Department of Commerce’s move to a department-wide, enterprise services model. For the White House, he led delegations to the Vatican, UN General Assembly and Aspen Ideas Festival. In the Clinton administration, he served as an advance staffer for President Clinton and as a Defense Fellow at the U.S. Department of Defense.
Upon leaving the public sector in 2017, Myers transitioned to Brooklyn-based Huge, Inc., working in a series of roles, most recently Vice President for Partnerships and Development, where he developed thought leadership platforms around autonomous vehicles, aerospace, maternal health and the future of work; created partnerships at SXSW, CES and Cannes, among others; and drove strategic growth for Huge’s Washington, D.C. office and global business. He then served as a Senior Vice President for San Francisco-based The OutCast Agency, charged with expanding the agency’s Washington, D.C. presence.
“Across my 25 years in campaigns, politics and public affairs, the one constant I have seen is how powerful it is when companies and organizations connect with people on their own turf about the issues they care about the most,” said Myers. “I have watched and marveled at the extraordinary work DI has done in this area and I jumped at the chance to lead this great team.”
Myers’ campaign experience includes working on Hillary for America 2016; Obama for America; John Edwards for President 2008; Kerry Edwards 2004; Gore/Lieberman 2000; Clinton/Gore 1996 and founding DC based Myers Strategies in 2004, focused on effective messaging through national grass roots events.
About Direct Impact
Founded in 1988, Direct Impact (DI) is a wholly owned subsidiary of BCW and a member of the WPP family. DI is a premier grassroots communications firm, specializing in public affairs, public education and corporate reputation campaigns. DI provides a complete range of services essential to conducting successful localized campaigns, focusing on legislative battles as well as corporate branding challenges across the country. DI has led winning, community-driven campaigns for more than half of the Fortune 50, as well as major trade associations and coalitions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005903/en/
Contact information
Media: Catherine Sullivan
Phone: 212.601.3205
Email:
Catherine.Sullivan@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
